Biopharmaceutical firm Gilead Sciences is taking 50,000 sq ft of workspace at One Triton Square, Regent’s Place in central London, landlords British Land and Royal London Asset Management have announced.
Regent’s Place, 1 Triton Square
Gilead Sciences develops medicines for serious diseases, with a focus on virology, oncology and other areas of unmet medical need.
“Gilead’s commitment to One Triton Square reflects the quality of this exceptional building and the ecosystem we are creating at Regent’s Place,” said Kelly Cleveland, head of real estate at British Land.
“The campus is the place where innovative businesses come to scale up, delivering next-generation technologies in a vibrant, future-focused location.
“The success of the building reinforces our conviction in taking strategic surrender premiums, upgrading space and securing high-quality lettings that unlock superior rents.”
The flagship development reached practical completion in October 2025 and has seen strong leasing activity, with five completed deals totalling 71,000 sq ft, including latest Gilead Sciences letting. The rest of the building is now 77% let or under offer by estimated rental value.
Mark Evans, head of property at Royal London Asset Management, said: “The leasing momentum the team have established stands to deliver strong investment returns to the fund and provides conviction for our underlying investment philosophy of deploying at scale into prime buildings in core, well-connected markets.”
One Triton Square provides over 300,000 sq ft of sustainable, purpose-built space, including fitted laboratories, flexible workspace, premium offices and shared meeting and event facilities.
Please visit:
Our Sponsor